Why the study?
No common consensus exists regarding the most adequate healthcare management policy for ACS during the Covid-19 pandemic, with varying practices across regions.
Answers are grounded in this paper and cite their sources.
This review highlights the need for optimal management strategies for ACS patients during the Covid-19 pandemic, given the potential pathophysiological links and observed underestimation of cases.
Since an association between myocardial infarction (MI) and respiratory infections has been described for influenza viruses and other respiratory viral agents, understanding possible physiopathological links between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and acute coronary syndromes (ACS) is of the greatest importance. The initial data suggest an underestimation of ACS cases all over the world, but acute MI still represents a major cause of morbidity and mortality worldwide and should not be overshadowed during the coronavirus disease (Covid-19) pandemic. No common consensus regarding the most adequate healthcare management policy for ACS is currently available. Indeed, important differences have been reported between the measures employed to treat ACS in China during the first disease outbreak and what currently represents clinical practice across Europe and the USA. This review aims to discuss the pathophysiological links between MI, respiratory infections, and Covid-19; epidemiological data related to ACS at the time of the Covid-19 pandemic; and learnings that have emerged so far from several catheterization labs and coronary care units all over the world, in order to shed some light on the current strategies for optimal management of ACS patients with confirmed or suspected SARS-CoV-2 infection.
No takes yet. Share an insight, caveat, or question.
Schiavone et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: